Clareo Health | Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
45–85
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participant has been postmenopausal for 3 years
Participant has BMD t-score at the total hip, hip trochanter, femoral neck, or lumbar spine ≥ -1.5 but \> -3.5
Participant has 2 hips that are evaluable by dual-energy X-ray absorptiometry (DXA) and quantitative computed tomography (QCT), e.g. contain no hardware from orthopedic procedures
Participant is ambulatory
You may not be if
Participant has had a previous hip fracture
Participant has had \>1 prior clinical vertebral fracture AND is a candidate for osteoporosis therapy
Participant has been treated with oral bisphosphonates, strontium, parathyroid hormone (PTH) or other agents with an effect on bone
Participant has had metabolic bone disorder other than osteoporosis
Participant has renal stones, Parkinson's disease, multiple sclerosis (MS) or active parathyroid disease.
